Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
Accel Entertainment's Growth Trajectory Strengthened by Strategic Fairmount Holdings Acquisition
Morgan Stanley Cuts STAAR to Underweight, Cites Growth Expectations
Bloom Energy's Bright Outlook: Buy Rating Affirmed Amid New Amazon Deal and Clean Tech Sector Potential
Wedbush Raises Price Target on Revolution Medicines to $59 From $46, Maintains Outperform Rating
Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Optimistic Buy Rating for Revolution Medicines' RMC-6236 Amid Favorable Clinical Data and Strategic Management Decisions
New York Community Analyst Ratings
Embecta Analyst Ratings
Nevro Analyst Ratings
IRhythm Technologies Analyst Ratings
Integra Lifesciences Analyst Ratings
Treace Medical Concepts Analyst Ratings
Humacyte Analyst Ratings
RxSight Analyst Ratings
SI-BONE Analyst Ratings
Glaukos Analyst Ratings
Vericel Analyst Ratings
Alphatec Holdings Analyst Ratings
Chart Industries Analyst Ratings